FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 493 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... July 16, 2024 EMA Recommends Extension of Indications for Darolutamide January 31, 2023 New Immunotherapy Option Approved for Cervical Cancer, Rare Lymphoma August 2, 2018 Load more HOT NEWS Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... New Drugs, New Side Effects: Complications of Cancer Immunotherapy The art of practicing sustainable science
